• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

不同年龄段人群中苯并(a)芘及其代谢物的生理基于药代动力学建模。

Physiologically-based pharmacokinetic modeling of benzo(a)pyrene and the metabolite in humans of different ages.

机构信息

School of Architecture and Art, Central South University , Changsha, HN, China.

XiangYa School of Public Health, Central South University , Changsha, China.

出版信息

Int J Environ Health Res. 2021 Mar;31(2):202-214. doi: 10.1080/09603123.2019.1640355. Epub 2019 Jul 12.

DOI:10.1080/09603123.2019.1640355
PMID:31296039
Abstract

Age-specific differences in the pharmacokinetics of benzo(a)pyrene (BaP) and its metabolite 3-hydroxybenzo(a)pyrene (3-OHBaP) potentially affect time courses of tissue concentration; however, the quantitative impact of these differences is not well characterized. Our objective was to quantify the effect of age-specific differences in physiological and biochemical parameters on the pharmacokinetics of BaP and 3-OHBaP from newborn at birth to adulthood following inhalation exposure. The time courses of BaP and 3-OHBaP were simulated by using a physiologically based pharmacokinetic model with Advanced Continuous Simulation Language (ACSLX). The concentrations of BaP increased with age in the liver but decreased with age in most tissues, urine, and blood. The concentrations of 3-OHBaP were the highest in the newborns. Our results also showed that the concentration of BaP has almost reached a steady state in the kidney, liver, lung, rapidly perfused tissues, slowly perfused tissues, and skin except for adipose tissues. However, the concentration of 3-OHBaP has reached a steady state in all tissues. This study suggests that age-specific parameters have an effect on the pharmacokinetics of BaP and 3-OHBaP. In particular, tissue concentration in the newborns is higher than other age groups, which indicates that the newborns are susceptible to environmental BaP exposure.

摘要

苯并(a)芘(BaP)及其代谢物 3-羟基苯并(a)芘(3-OHBaP)的药代动力学在不同年龄段存在差异,这可能会影响组织浓度的时间过程;然而,这些差异的定量影响尚未得到很好的描述。我们的目的是量化生理和生化参数在特定年龄段的差异对吸入暴露后从新生儿到成年期 BaP 和 3-OHBaP 药代动力学的影响。使用基于生理的药代动力学模型和高级连续模拟语言(ACSLX)来模拟 BaP 和 3-OHBaP 的时间过程。BaP 的浓度随着年龄的增长在肝脏中增加,但在大多数组织、尿液和血液中随着年龄的增长而降低。3-OHBaP 的浓度在新生儿中最高。我们的结果还表明,BaP 的浓度在肾脏、肝脏、肺、快速灌注组织、缓慢灌注组织和皮肤(脂肪组织除外)中几乎达到稳定状态。然而,3-OHBaP 的浓度在所有组织中均达到稳定状态。本研究表明,特定年龄段的参数对 BaP 和 3-OHBaP 的药代动力学有影响。特别是,新生儿组织中的浓度高于其他年龄组,这表明新生儿易受环境 BaP 暴露的影响。

相似文献

1
Physiologically-based pharmacokinetic modeling of benzo(a)pyrene and the metabolite in humans of different ages.不同年龄段人群中苯并(a)芘及其代谢物的生理基于药代动力学建模。
Int J Environ Health Res. 2021 Mar;31(2):202-214. doi: 10.1080/09603123.2019.1640355. Epub 2019 Jul 12.
2
Understanding the linked kinetics of benzo(a)pyrene and 3-hydroxybenzo(a)pyrene biomarker of exposure using physiologically-based pharmacokinetic modelling in rats.利用大鼠生理相关药代动力学模型理解苯并(a)芘和 3-羟基苯并(a)芘生物标志物暴露的连锁动力学。
J Pharmacokinet Pharmacodyn. 2013 Dec;40(6):669-82. doi: 10.1007/s10928-013-9338-9. Epub 2013 Oct 29.
3
Modeling of the internal kinetics of benzo(a)pyrene and 3-hydroxybenzo(a)pyrene biomarker from rat data.苯并(a)芘和 3-羟基苯并(a)芘生物标志物的大鼠体内动力学建模。
Toxicol Sci. 2011 Aug;122(2):275-87. doi: 10.1093/toxsci/kfr135. Epub 2011 May 24.
4
Use of physiologically-based pharmacokinetic modeling to simulate the profiles of 3-hydroxybenzo(a)pyrene in workers exposed to polycyclic aromatic hydrocarbons.使用基于生理学的药代动力学模型来模拟接触多环芳烃的工人中3-羟基苯并(a)芘的分布情况。
PLoS One. 2014 Jul 17;9(7):e102570. doi: 10.1371/journal.pone.0102570. eCollection 2014.
5
A toxicokinetic study to elucidate 3-hydroxybenzo(a)pyrene atypical urinary excretion profile following intravenous injection of benzo(a)pyrene in rats.阐明静脉注射苯并[a]芘后大鼠 3-羟基苯并[a]芘非典型尿排泄特征的毒代动力学研究。
J Appl Toxicol. 2010 Jul;30(5):402-10. doi: 10.1002/jat.1511.
6
Predicting lung dosimetry of inhaled particleborne benzo[a]pyrene using physiologically based pharmacokinetic modeling.使用基于生理的药代动力学模型预测吸入颗粒态苯并[a]芘的肺部剂量学
Inhal Toxicol. 2016 Sep;28(11):520-35. doi: 10.1080/08958378.2016.1214768.
7
Comparison of the kinetics of various biomarkers of benzo[a]pyrene exposure following different routes of entry in rats.大鼠经不同途径接触苯并[a]芘后各种生物标志物动力学的比较。
J Appl Toxicol. 2015 Jul;35(7):781-90. doi: 10.1002/jat.3070. Epub 2014 Oct 27.
8
Urinary excretion of benzo[a]pyrene metabolites following intravenous, oral, and cutaneous benzo[a]pyrene administration.
Can J Physiol Pharmacol. 1997 Mar;75(3):185-92. doi: 10.1139/cjpp-75-3-185.
9
Predicting the in vivo developmental toxicity of benzo[a]pyrene (BaP) in rats by an in vitro-in silico approach.采用体外-计算方法预测苯并[a]芘(BaP)在大鼠体内发育毒性。
Arch Toxicol. 2021 Oct;95(10):3323-3340. doi: 10.1007/s00204-021-03128-7. Epub 2021 Aug 25.
10
3-Hydroxybenzo(a)pyrene as a biomarker of dermal exposure to benzo(a)pyrene.3-羟基苯并(a)芘作为皮肤接触苯并(a)芘的生物标志物。
Arch Toxicol. 2009 Sep;83(9):873-83. doi: 10.1007/s00204-009-0440-0. Epub 2009 Jun 13.

引用本文的文献

1
[Progress in the metabolic and biotransformation of polycyclic aromatic hydrocarbons and their derivatives in humans].[多环芳烃及其衍生物在人体中的代谢与生物转化研究进展]
Se Pu. 2025 Jun;43(6):571-584. doi: 10.3724/SP.J.1123.2024.11030.